Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients by Fujita, K et al.
Approximately 30% of patients with renal cell carcinoma (RCC)
have evidence of metastasis at the time of diagnosis. In a signifi-
cant number of patients, the metastasis occurs after surgery with
curative intent. The most common target organs of metastasis
are the lung, bone, liver and lymph nodes (Holland, 1973).
Chemotherapy and radiotherapy are not effective in patients with
metastatic RCC (van der Werf-Messing, 1973; Fojo et al, 1987).
Administration of biologic response modifiers such as interferon
(IFN)-a, IFN-g and interleukin-2 elicited responses in 10–27% of
the patients, but the duration of the response was limited (Umeda
and Niijima, 1986; Sarna et al, 1987; Dreicer and Williams, 1995).
Consequently, the presence or emergence of metastasis indicates a
dismal prognosis, and the 5-year survival rate of RCC patients
with metastasis is reported to be less than 20% (Dreicer and
Williams, 1995; Giberti et al, 1997).
It is thought that not all tumour cells in a primary lesion are able
to metastasize to distant organs. Tumour cells with a high
metastatic potential arise within primary tumours at an early stage
and become predominant during the progression of the disease to
an advanced stage (Poste and Fidler, 1980; Irimura et al, 1993).
The glycoproteins expressed on the tumour cells of a metastatic
phenotype are qualitatively and quantitatively different from those
of the non-metastatic phenotype (Nicolson, 1982; Irimura and
Reading, 1987; Matsushita et al, 1990; Irimura et al, 1991). Some
altered glycoproteins presumably affect the behaviour of the cell
during the process of metastasis, i.e. release of tumour cells from
the primary lesion, invasion of vessels, adhesion to endothelial
cells and escape from immune recognition (Ponta et al, 1994).
Detection of such altered glycoproteins in surgical specimens may
provide information regarding the potential of metastasis after the
surgery.
MUC1 mucin (also known as episialin, PUM, PEM and
epitectin) is one of the glycoproteins expressed by the metastatic
phenotype (Hilkens et al, 1992; Nakamori et al, 1994; Gendler and
Spicer, 1995). MUC1 mucin is a transmembrane glycoprotein with
a large extracellular domain that extends 200–500 nm above the
cell membrane. The protein backbone of the extracellular domain
consists of 30–90 repeats of 20 amino acids that are nearly
identical (Gendler et al, 1990; Lan et al, 1990; Hilkens et al, 1992).
Proline residues make the protein backbone straight, and serine
and threonine residues, which are O-glycosylated, make the struc-
ture very rigid (Jentoft, 1990). These O-linked glycans are fully
sialylated during the maturation of MUC1 mucin through a trans-
Golgi network (Litvinov and Hilkens, 1993).
Sialylated MUC1 mucin expressed on cancer cells suppresses
homotypic cellular aggregation (Ligtenberg et al, 1992) and cell-
matrix adhesion and promotes invasion in Matrigel (Hilkens et al,
1993). Moreover, sialylated MUC1 mucin inhibits cytotoxic
lymphocyte–target cell interactions in vitro (Irimura et al, 1990).
These molecules also induced apoptosis of lymphocytes (Gimmi
et al, 1996; Agrawal et al, 1998). Thus, the findings to date suggest
that cancer cells in vivo with a high level of expression of sialyl-
ated MUC1 mucin may be able to detach easily from the primary
lesion and survive in circulation or in distant organs of metastasis
by escaping from immune surveillance.
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Summary Surgical specimens of the normal kidney and of renal cell carcinoma (RCC) tissues at different stages of progression and of
various histological grades were examined for the expression of MUC1 mucins with sialylated carbohydrates (sialylated MUC1 mucins) using
a monoclonal antibody MY.1E12. Immunohistochemical studies revealed that the binding sites for this antibody were localized to the apical
side of the epithelial cells of the distal convoluted tubules, Henle’s loops and collecting ducts. However, proximal convoluted tubules, where
RCC is considered to originate, were not stained. This antibody also bound strongly to RCC at advanced stages of progression and at
metastatic sites, and to RCC of histologically high grades (undifferentiated). The epitope, presumably sialylated MUC1 mucin, was detected
not only along the surface of the cell membranes but also in the cytoplasm. The level of expression of sialylated MUC1 mucins was inversely
correlated with the survival of the patients with RCC and the disease-free survival period after curative surgery. Western blot analysis
demonstrated that the electrophoretic mobility of sialylated MUC1 mucins of RCC was greater than that from the normal kidney. It is
suggested that high levels of expression of sialylated MUC1 mucins in certain human RCC populations correlate with the aggressiveness of
the disease, such as the tendency to form metastasis.
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Correspondence to: T IrimuraPreviously, we generated a novel monoclonal antibody (mAb),
MY.1E12, which preferentially recognizes sialylated MUC1
mucin (Yamamoto et al, 1996). In this study, we used mAb
MY.1E12 to detect sialylated MUC1 mucin in formalin-fixed,
paraffin-embedded surgical specimens from RCC of various histo-
logical grades and at different stages of progression. A correlation
between the level of expression of sialylated MUC1 mucin and the
survival of patients was demonstrated.
MATERIALS AND METHODS
Specimens
Fifty-one specimens of RCC were obtained from patients who had
undergone radical nephrectomy at Juntendo University. All speci-
mens were classified by pathologists according to the TNM
system (International Union Against Cancer, 1987) UICC staging
(International Union Against Cancer, 1992) and pathological
grading based on the nuclear atypia (Japanese Urological
Association, 1992). In half of the cases, the renal cortex, medulla
and carcinoma were sampled before formalin fixation and were
kept frozen at –80°C until use. Specimens from metastatic sites
were also obtained from autopsy cases.
A cell line and a mAb
Capan-1 pancreatic adenocarcinoma cell lines were obtained from
Dr Marsha L Frazier of the Department of Epidemiology, The
University of Texas, MD Anderson Cancer Center, Houston, TX,
USA. The cells were maintained in a 1:1 mixture of Dulbecco’s
modified Eagle’s medium and Ham’s F12 medium that contained
10% fetal calf serum in a humidified atmosphere that contained
5% carbon dioxide at 37°C. mAb MY.1E12 (IgG2a), specific for
MUC1 mucin with sialylated O-linked oligosaccharides, was
prepared as described previously (Yamamoto et al, 1996). The
epitope structure recognized by this mAb was previously
described (Yamamoto et al, 1996).
Immunohistochemical staining
Surgical specimens fixed in formalin and embedded in paraffin
were cut at 4 mm. The sections were deparaffinized and treated
with 0.3% hydrogen peroxide in methanol for 30 min to block
endogenous peroxidase activity. The sections were rehydrated in
phosphate-buffered saline (PBS) and incubated with 2% bovine
serum albumin (BSA) in PBS for 40 min at room temperature
(r.t.). mAb MY.1E12 (culture supernatant of the hybridoma cells)
was diluted 1:1 in PBS containing 2% BSA. The sections were
incubated with the diluted mAb MY.1E12 for 1 h at 37°C. After
washing with PBS, the sections were incubated with biotinylated
goat anti-mouse immunoglobulin (DAKO JAPAN Co., Ltd,
Kyoto, Japan) for 40 min at r.t. The specimens were washed with
PBS and incubated with a solution of horseradish peroxidase-
conjugated streptavidin (DAKO JAPAN Co., Ltd) for 40 min at r.t.
After repeated washing, they were treated with DAB reagent,
which consisted of a 0.05% solution of 3,3¢-diaminobenzidine
(Sigma, St Louis, MO, USA) dissolved in 10 ml of PBS and 3 ml
of 30% hydrogen peroxide. The specimens were counterstained
with haematoxylin.
In some experiments, deparaffinized and hydrogen peroxidase-
treated sections were incubated with sialidase (Vibrio cholerae,
50 mU ml–1 in PBS; Calbiochem, La Jolla, CA, USA) at 37°C
for 3 h (Matsushita et al, 1990). After several washings with PBS,
the sections were treated with mAb MY.1E12 and processed as
described above.
Western blot analysis
The frozen surgical specimens were thawed and homogenized with
0.5% Nonidet P-40 in a desalting buffer that consisted of
250 mM sucrose, 10 mM Tris-HCl, 50 mM calcium chloride and
10 mM phenylmethylsulphonyl fluoride, pH 7.2. The Capan-1 cells
were also lysed in the same buffer. The supernatants of the lysates
were mixed with one half volume of 187.5 mM Tris-HCl that
contained 5% sodium dodecyl sulphate, 3% 2-mercaptoethanol,
30% glycerol and 1.5 mM EDTA. The mixtures containing 200 mg
of protein were heated for 5 min at 100°C and then electrophoreti-
cally separated on 4% polyacrylamide gels in the presence of 0.1%
sodium dodecyl sulphate (SDS-PAGE). They were transblotted
onto polyvinylidene difluoride membranes (Immobilon; Millipore,
Boston, MA, USA). The membranes were incubated in 2% BSA in
PBS at 4°C overnight and then mixed with mAb MY.1E12 (culture
supernatant of hybridoma cells) diluted in an equal volume of 2%
BSA for 2 h at r.t. After washing with PBS that contained 0.1%
Tween-20, they were incubated with rabbit anti-mouse IgG labelled
with alkaline phosphatase (Zymed Laboratories Inc., San Francisco,
CA, USA) for 1 h at r.t. The membranes were washed with PBS that
contained 0.1% Tween-20 and then treated with ECL (Amersham,
Buckinghamshire, UK) to visualize the antibodies that were bound.
Statistical analysis
Statistical analysis was performed using Student’s t-test. The
survival of patients and recurrence of disease were recorded every
month. Patient survival was analysed by the method of Kaplan and
Meier (1977). Disease-free survival of patients undergoing cura-
tive surgery was analysed by the same method. Differences in the
survival of patients in subgroups that were classified according to
reactivity with mAb MY.1E12 were analysed by the log-rank test.
RESULTS
Immunohistochemical localization of sialylated MUC1
mucin in normal kidney
The luminal surfaces of the distal convoluted tubules, collecting
ducts and Henle’s loops were strongly stained with mAb
MY.1E12, but the proximal convoluted tubules and Bowman’s
capsules were not (Figure 1). This reactivity with mAb MY.1E12
was completely abolished by sialidase treatment of the specimens
(data not shown).
Immunohistochemical localization of sialylated MUC1
mucin in RCC
The staining pattern of mAb MY.1E12 in RCC demonstrated that
the distribution of sialylated MUC1 mucin in the tumour was
heterogeneous. A cell was judged to be positively stained when
either the cytoplasm or the whole cell membrane was stained.
Conversely, when only the apical side of the membrane was
stained it was judged to be negative. To quantitate the degree of
reactivity with mAb MY.1E12, the percentage of positively
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Figure 1 Immunohistochemical staining of normal kidney tissues with mAb MY.1E12. Sialylated MUC1 mucins were detected in Henle’s loops, distal
convoluted tubules and collecting ducts. Bars at the bottom left of the panels indicate 300 mm for (A) and 100 mm for (B), respectively
Table 1 Expression of sialylated MUCI mucin in 51 RCC specimens
Positive ratea
Variables No. (mean ± s.d.) Difference Probability
Age
< 60 28 56.6 ± 45.5
³ 60 vs < 60 NSb
³ 60 23 54.7 ± 43.2
Sex
Male 37 52.5 ± 44.4
Male vs Female NS
Female 14 64.2 ± 43.4
Size of tumour
< 6.0 cm 21 42.3 ± 45.0
³ 6.0 cm vs < 6.0 cm NS
³ 6.0 cm 30 65.1 ± 41.5
T classification
T1 2 10.0 ± 14.1
T2 30 52.6 ± 45.4
T1 + T2 vs T3 + T4 NS
T3 17 61.4 ± 41.8
T4 2 100 ± 0
N classification
N0 42 50.1 ± 44.4
N0 vs N1–3 P < 0.05
N1–3 9 82.2 ± 32.7
M classification
M0 32 37.3 ± 43.8
M0 vs M1 P < 0.001
M1 19 86.8 ± 21.6
Pathological grading
Grade 1 21 22.8 ± 36.7
Grade 1 vs Grade 2 + Grade 3 P < 0.001
Grade 2 17 75.8 ± 32.4
Grade 1 + Grade 2 vs Grade 3 P < 0.05
Grade 3 13 82.6 ± 34.4
UICC staging
Stage 1 2 10.0 ± 14.1
Stage 1 vs Stage 2 + 3 + 4 NS
Stage 2 19 31.5 ± 42.1
Stage 1 + 2 vs Stage 3 + 4 P < 0.001
Stage 3 11 52.2 ± 47.6
Stage 1 + 2 + 3 vs Stage 4 P < 0.001
Stage 4 19 86.8 ± 21.6
aThe percentage of positively stained cells in the tumour cells. bNot significant.stained cells in all tumour cells (positive rate) was determined for
each specimen. The levels of expression of sialylated MUC1
mucin in 51 surgical specimens of RCC are summarized in
Table 1.
Primary tumours that had already metastasized to distant organs
(M1) were stained more strongly than tumours that had not metas-
tasized (M0) (P < 0.001). Moreover, primary tumours that had
metastasized to the regional lymph nodes (pN1–3) were also
stained more strongly than the tumours that had not (pN0)
(P < 0.05). No difference in reactivity was found between tumours
that were limited to the kidney (pT1–2) and those that had invaded
beyond the kidney (pT3–4). Reactivity to the antibody was not
affected by the size of the tumour or the age and sex of the
patients. RCC at UICC stage 3 or 4 (advanced stage of cancer
progression) showed higher expression of sialylated MUC1 mucin
than RCC at stage 1 or 2 (P < 0.001).
This pathologic grading used in the study presented here is
based on the nuclear atypia of the tumour. Grade 1 tumours, which
had nuclei resembling the nuclei of proximal convoluted tubule
cells, showed weak reactivity with the mAb (Figure 2). Grade 2
tumours, which had larger or irregular nuclei with nucleoli,
showed moderate reactivity (Figure 3). Grade 3 tumours, which
had bizarre or giant nuclei, reacted strongly with the mAb (Figure
4). Sialidase treatment completely abolished the reactivity of the
RCC specimens with mAb MY.1E12.
Tissues of metastasis of distant organs were obtained from six
autopsy cases. The immunohistochemical reactivity to MY.1E12
was high for all the tissues (positive rate: 69.0 ± 40.4).
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Figure 2 Immunohistochemical staining of grade 1 RCC with mAb
MY.1E12. A bar at the bottom left of the panel corresponds to 100 mm
A
B
Figure 3 Immunohistochemical staining of grade 2 RCC with mAb
MY.1E12. Bars at the bottom left of the panels correspond to 100 mm for (A)
and (B)
Figure 4 Immunohistochemical staining of grade 3 RCC with mAb
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Figure 5 Relationship between the prognosis and expression of sialylated
MUC1 mucins in the RCC specimens by Kaplan–Meier’s survival curve. The
patients with RCC were divided into two groups according to the percentage
of stained cells in the cancer specimens: Group A, which had greater or
equal to 5% of the cells stained, and Group B, which had less than 5% of the
cells stained (P = 0.009 according to the log-rank test)Relationship between the prognosis or disease-free
survival of patients with RCC and expression of
sialylated MUC1 mucin in the specimens
The patients with RCC were divided into two groups according to
the percentage of stained cells in the cancer specimens: Group A,
which had greater or equal to 5% of the cells stained, and Group B,
which had less than 5% of the cells stained. The survival curves of
the patients in these two groups were drawn by the method of
Kaplan–Meier (Figure 5). The prognosis of the patients in Group
A was significantly poorer than that of the patients in Group B
(P = 0.009). The 5-year survival rate was 47.2% in Group A and
85.7% in Group B. The disease-free survival of patients who had
undergone curative surgery is shown in Figure 6. It should be
noted that none of the patients subjected to this comparison had
detectable metastasis at the time of surgery. The patients in Group
A developed metastasis more frequently than the patients in Group
B (P = 0.034). The survival curves were also compared within
restricted categories. In Figure 7A, a total of 27 patients who did
not have detectable metastasis at the time of surgery (N0M0) were
compared according to mAb MY.1E12 binding. The difference
between the MUC1 mucin-positive group and MUC1 mucin-nega-
tive group was statistically significant (P = 0.043). When a total of
32 patients categorized as T1 and T2 (confined tumours) were
compared, significant difference in the survival between patients
with stained tumours and unstained tumours was also observed
(P = 0.010) (Figure 7B). Patients with MUC1 mucin-positive
tumours showed significantly poorer survival than those with
MUC1 mucin-negative tumours (P = 0.014), when patients with
tumour cells having grade 1 and grade 2 nuclear atypia were exam-
ined (Figure 7C).
Western blot analysis of sialylated MUC1 mucin in
normal kidney, RCC and Capan-1 cell lines
Normal kidney tissues were obtained from an area approximately
3 cm from the primary RCC. The cortex and medulla of the normal
tissue were separated macroscopically. The cortex contained distal
and proximal convoluted tubules and Bowman’s capsules. The
medulla contained collecting ducts and Henle’s loops. Sialylated
MUC1 mucins in renal cell carcinoma 305
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Figure 6 Relationship between disease-free survival and expression of
sialylated MUC1 mucins in the RCC specimens by Kaplan–Meier’s survival
curve. Groups A and B represent the same categories as in Figure 5




























     
     
     
     
 
                             
             
           
             
                   
     
       
     
 
           
Figure 7 Relationship between prognosis and mAb MY.1E12 binding to
RCC tissues by Kaplan–Meier’s survival curve within three subcategories of
patients. (A) Patients classified as N0M0 (P = 0.043 according to the log-rank
test). (B) Patients classified as T1 and T2 (P = 0.010 according to the log-
rank test). (C) Patients classified as grade 1 and grade 2 (P = 0.014
according to the log-rank test). Groups A and B represent the same
categories as in Figure 5MUC1 mucin in the lysates of the normal cortex and medulla,
RCC and Capan-1 cell lines was detected with mAb MY.1E12
after SDS-PAGE (Figure 8). When normal tissue and RCC from
the same patients were compared, normal tissue contained compo-
nents with slower mobility than RCC. RCC and Capan-1 cells
from one patient (lane 8) apparently contained two distinct bands
corresponding to two alleles of MUC1 gene. Sialylated MUC1
mucin of RCC from five patients (corresponding to lanes 4, 6, 7, 9
and 10) had similar electrophoretic migration corresponding to an
apparent Mr 400 000.
DISCUSSION
The expression of MUC1 mucin by RCC at various stages of
progression was demonstrated. Primary lesions with distant organ
metastasis (M1) or lymph node metastasis (pN1–3) were stained
more strongly by the mAb specific for sialylated MUC1 mucin
than lesions without metastasis (P < 0.001 and 0.05 respectively).
Among patients who had undergone surgery with curative intent
for localized cancer (pT1–3, pN0, M0), the patients with a high
level of MUC1 mucin expression had a poorer disease-free
survival rate than the patients with a low level of MUC1 mucin
expression (P < 0.05). These results indicate that RCC cells with
high MUC1 mucin expression have a strong potential for metas-
tasis, and that micrometastases may already exist at the time of
surgery if the expression of MUC1 mucin was high at the primary
lesion. There were no significant differences in MUC1 mucin
expression between cancer that was confined within the kidney
(pT1–2) and cancer that was invasive through the renal capsule
into the perinephric fat (pT3–4). The size of the tumour did not
affect the expression of MUC1 mucin. These results are consistent
with our previous findings on colon carcinoma cells indicating that
primary tumours at advanced stages expressed increased levels of
MUC1 mucin (Nakamori et al, 1994).
RCC cells were histologically divided into three grades based
on the degree of nuclear atypia (Japanese Urological Association,
1992). RCCs in grade 1 (well-differentiated) had nuclei which
resembled that of proximal convoluted tubules. These RCCs
expressed MUC1 mucin weakly and the cells sometimes preserved
the polar nature of its localization. Most RCCs in grade 2 or 3
(moderately or poorly differentiated) expressed MUC1 mucin
strongly at the surface of the cell membranes and in the cytoplasm.
Due to such strong association with histological grades and stages
of the disease, the increased sialylated MUC1 mucin revealed by
mAb MY.1E12 is not considered to be an independent prognostic
marker. However, this phenotype should serve as a unique biolog-
ical feature associated with advanced RCC.
MUC1 mucin is a long and rigid glycoprotein that extrudes out
of the cell membrane and is negatively charged due to the addition
of sialic acids. In normal glandular cells, MUC1 mucin is
expressed only on the apical (luminal) side of the cells. The charge
repulsion caused by the sialic acids and the rigid structures of the
mucins apparently maintain the lumen of the gland and prevent
attachment of foreign molecules or cells. In most cancer cells, this
polarization is lost and overexpression of MUC1 mucin on the
whole cell membrane is believed to destabilize the cell–cell adhe-
sion and to permit cancer cells to migrate and metastasize (Hilkens
et al, 1992). This tendency to lose homotypic cell adhesion was
experimentally observed under the influence of a potent adhesion
molecule, E-cadherin, as reported by Hilkens and co-workers.
They used double transfectant cells that expressed both MUC1
mucin and E-cadherin to show that MUC1 mucin could prevent
intercellular adhesion mediated by E-cadherin (Hilkens et al,
1993; Wesseling et al, 1996). In these studies, however, sialic acid
at the termini of carbohydrate chains did not seem to play roles.
Although the present study utilized with a mAb specific for sialy-
lated MUC1 mucin, our preliminary experiments with mAb
specific for core polypeptide portions of MUC1 mucin also
showed similar differences in their bindings to low- and high-
grade RCC. A decrease in E-cadherin function was proposed to
favour the detachment of cells in most carcinomas, resulting in a
more aggressive tumour (Takeichi, 1991; Birchmeier and Behrens,
1994). However, the frequency of expression of E-cadherin in
RCC seems to be very low regardless of the grade. Even low-grade
RCCs do not express E-cadherin. Furthermore, the normal prox-
imal convoluted tubules, where RCC is considered to originate
(Oosterwijk et al, 1986; Mackay et al, 1987), do not express E-
cadherin (Terpe et al, 1993; Katagiri et al, 1995). Therefore,
MUC1 mucin may be antagonizing other adhesion molecules in
RCC.
As stated above, RCC originates from the proximal convoluted
tubules. Our immunohistochemical study of normal kidney tissues
demonstrated that MUC1 mucin is absent in the proximal convo-
luted tubules, but present on cell surfaces of the distal convoluted
tubules, collecting ducts and Henle’s loops. MUC1 mucin is
detected mainly on the apical side of these cells. In the process of
malignant transformation from the proximal convoluted tubules,
RCC cells acquire the ability to express MUC1 mucin.
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Figure 8 Binding of mAb MY.1E12 to electrophoretically separated lysates
of normal kidney tissues, RCC and Capan-1 cells. Lane 1 is the lysate of
Capan-1 cells. Lane 2 is the lysate of the normal medulla of the kidney,
which contains Henle’s loops and collecting ducts. Lane 3 is the lysate of the
normal cortex of the kidney, which contains Bowman’s capsules, proximal
convoluted tubules and distal convoluted tubules. Lane 4 is the lysate of
grade 2, pT3N0M1 RCC. Lane 5 is the lysate of the normal cortex of the
kidney. Lane 6 is the lysate of grade 2, pT3N0M0 RCC. Lane 7 is the lysate
of grade 1, pT2N0M0 RCC. Lane 8 is the lysate of grade 3, pT3N1M1 RCC.
Lane 9 is the lysate of grade 2, pT2N0M1 RCC. Lane 10 is the lysate of
grade 3, pT2N0M1 RCC. These cell lysates were subjected to SDS-PAGE
using 4% gels, followed by blotting onto polyvinylidene difluoride
membranes. The membranes were processed for detection of sialylated
MUC1 mucin, as described in Materials and Methods. Samples obtained
from the same patient are bracketedElectrophoretic analysis revealed slight differences in the apparent
Mr of MUC1 mucin expressed in malignant cells and normal cells
(collecting ducts, distal convoluted tubules and Henle’s loops).
Such altered glycosylation and sialylation in RCC might influence
the reactivity of MUC1 mucin with MY.1E12. Thus, there is a
possibility that this antibody does not react with a portion of a
mixture of diversely glycosylated MUC1 mucin, resulting in
unique banding patterns revealed by Western blot analysis. It
remains to be elucidated whether these differential migrations
were due to changes in the number of O-linked carbohydrate
chains or extension of carbohydrate chains.
van der Wiel-van Kemenade et al (1993) reported that
melanoma cells transfected with MUC1 genes are resistant to
killing by cytotoxic T-cells and lymphokine-activated killer cells.
We reported previously that colon carcinoma cells with high
MUC1 mucin production are less sensitive to cytolysis by
lymphokine-activated killer cells (Irimura et al, 1990). These data
suggest that a greater amount of MUC1 mucin on RCC cells may
conceal putative recognition sites for these killer lymphocytes.
This would increase the chance of survival and colonization of
RCC cells by allowing them to evade immune surveillance. It is
also possible that the alteration in MUC1 mucin expression is
simply associated with the status of differentiation of RCC and
may not influence the cells’ malignant behavior.
The mechanistic basis for the increase of mAb MY.1E12-reac-
tive MUC1 mucin in high-grade RCC is not known. Host micro-
environmental factors may affect the production of MUC1 mucin.
We reported that a soluble factor, produced by connective tissue of
the colon, increased the expression of MUC1 mucin by colon
carcinoma cells in vitro (Irimura et al, 1990; Dohi et al, 1993;
Shirotani et al, 1994). A higher level of expression of MUC1
mucin was observed in RCC cells adjacent to the connective tissue
of the kidney (Figure 3B), suggesting that a similar protein that
increases expression of MUC1 mucin may be produced by the
interstitium of the kidney.
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